8 result(s) for Leukemia
| PI Name | Protocol # | Title |
|---|---|---|
| Richard Maziarz | IRB00000210 | A Phase II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation |
| Kim-Hien Dao | IRB00005669 | A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients with Chronic Myelomonocytic Leukemia (CMML) |
| Stephen Spurgeon | IRB00006550 | A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) or B-Cell Lymphoma |
| Richard Maziarz | IRB00006928 | CALGB 100701/BMT CTN 0804: Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) |
| Stephen Spurgeon | IRB00007195 | A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies |
| Andy Chen | IRB00007406 | An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDT2980S in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma |
| Gabrielle Meyers | IRB00007422 | A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia |
| Richard Maziarz | IRB00008664 | A randomized, prospective, double blind, placebo-controlled, phase 3 study of US- ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors (IV-ATG-SCT-01) |
You may qualify for additional trials within our Phase 1 Program